Published Date: 02 Mar 2023
The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.
Read Full NewsShroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.
Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.
1.
FDA Expands Approval of Osimertinib in Lung Cancer
2.
Study sets benchmark for treatment of advanced cervical cancer
3.
Sickle Cell Disease Drug Pulled From Global Markets
4.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'
5.
the contribution of cortactin to the development of cancer.
1.
The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia
2.
Oncologic Emergencies: Diagnosis and Treatment
3.
Introduction To Immune Thrombocytopenic Purpura
4.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
5.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part III
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation